Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXE408 in Chronic Chagas Disease
NCT06632600Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2025
- Primary completion
- Jul 2027
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of LXE408 in Chagas disease (4 arms), sponsored by Novartis. Primary endpoint: Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo. Started Apr 2025; status: recruiting.
02
Drugs
LXE408
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT06632600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632600.